Insider Transactions in Q3 2022 at Veracyte, Inc. (VCYT)
Insider Transaction List (Q3 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 02
2022
|
Marc Stapley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,012
-0.63%
|
$19,228
$19.18 P/Share
|
|
Sep 02
2022
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,008
-1.44%
|
$19,152
$19.18 P/Share
|
|
Sep 02
2022
|
Rebecca Chambers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,023
-3.94%
|
$57,437
$19.18 P/Share
|
|
Sep 02
2022
|
Bonnie H Anderson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,042
-3.05%
|
$38,798
$19.18 P/Share
|
|
Aug 09
2022
|
Eliav Barr Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,721
+50.0%
|
-
|
|
Aug 08
2022
|
Bonnie H Anderson Director |
SELL
Open market or private sale
|
Indirect |
45,000
-14.9%
|
$1,215,000
$27.53 P/Share
|
|
Aug 05
2022
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
1,028
-1.45%
|
$26,728
$26.54 P/Share
|
|
Aug 05
2022
|
Giulia C Kennedy Chief Scientific & Med Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5
+0.0%
|
$35
$7.44 P/Share
|
|
Aug 05
2022
|
Giulia C Kennedy Chief Scientific & Med Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,702
+13.09%
|
-
|
|
Aug 05
2022
|
Bonnie H Anderson Director |
SELL
Open market or private sale
|
Indirect |
76,917
-32.82%
|
$2,076,759
$27.71 P/Share
|
|
Aug 05
2022
|
Rebecca Chambers Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,404
+21.81%
|
-
|
|
Aug 05
2022
|
Jonathan Wygant VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,561
+29.4%
|
-
|
|
Aug 05
2022
|
Annie Mc Guire SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
10,702
+24.18%
|
-
|